Yellow Card reports for liraglutide more generally record a higher rate of serious adverse effects, but a lower total of reports overall, which may reflect less widespread use of the drug 27
Alcohol and melatonin
Your first point of contact for any concerns about your trial medication should be your trial team , who are best placed to assess whether symptoms may be related to the investigational medicine and to advise on next steps
In the wider literature, established evidence from randomised controlled trials, albeit in non-CKD populations, generally support GLP-1 RAs (notably once-daily semaglutide over 52 weeks) for HbA1c and weight benefits, owing to the strength of evidence demonstrating their role in body weight, glycaemic and blood pressure reduction [25, 27]
Record daily doses, injection sites, and any side effects to monitor consistency and tolerance
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally